OverviewSuggest Edit

Eagle Pharmaceuticals is a specialty pharmaceutical company, focusing on developing and commercializing injectable products primarily in the critical care and oncology areas. The Company offers argatroban for heparin-induced thrombocytopenia, Ryanodex for malignant hyperthermia, non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head and neck cancers/gastric adenocarcinoma, as well as Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

TypePublic
Founded2007
HQWoodcliff Lake, NJ, US
Websiteeagleus.com

Latest Updates

Employees (est.) (Dec 2019)108(+13%)
Revenue (FY, 2019)$195.9 M(-8%)
Share Price (Feb 2021)$50.5 (+2%)
Cybersecurity ratingBMore

Key People/Management at Eagle Pharmaceuticals

Michael W. Cordera

Michael W. Cordera

Executive Vice President, General Counsel & Chief Compliance Officer
Scott Tarriff

Scott Tarriff

Founder, Chief Executive Officer and Director
Daniel OConnor

Daniel OConnor

Chief Strategy Officer, Head of Corporate Development
David Pernock

David Pernock

President, Chief Operating Officer
Brian Cahill

Brian Cahill

Chief Financial Officer
Michael Moran

Michael Moran

Executive Vice President Sales, Business Development and Government Affairs
Show more

Eagle Pharmaceuticals Office Locations

Eagle Pharmaceuticals has offices in Woodcliff Lake and Chicago
Woodcliff Lake, NJ, US (HQ)
50 Tice Blvd #315
Chicago, IL, US
Chicago, IL, USA
Show all (2)

Eagle Pharmaceuticals Financials and Metrics

Eagle Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Eagle Pharmaceuticals's revenue was reported to be $195.89 m in FY, 2019
USD

Revenue (Q3, 2020)

17.3m

Market capitalization (8-Feb-2021)

657.4m

Closing stock price (8-Feb-2021)

50.5

Cash (30-Sept-2020)

89.7m

EV

605.5m
Eagle Pharmaceuticals's current market capitalization is $657.4 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

19.1m66.2m189.5m236.7m213.3m195.9m

Revenue growth, %

247%186%

Cost of goods sold

11.7m15.6m34.3m33.7m42.4m47.9m

Gross profit

7.4m50.6m155.2m203.0m170.9m148.0m
Quarterly
USDQ2, 2014Q3, 2014Q4, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

5.0m5.8m5.6m36.3m6.0m5.7m29.6m40.9m37.8m76.8m50.1m63.0m46.6m59.3m51.3m49.8m56.7m41.1m46.0m14.4m17.3m

Cost of goods sold

3.4m1.6m4.5m5.9m3.3m3.8m14.6m11.5m10.4m10.8m8.9m4.8m7.2m14.1m8.6m9.6m18.2m12.1m4.8m

Gross profit

1.6m4.2m1.1m30.4m2.7m2.0m15.0m29.4m27.4m66.0m41.2m58.2m39.4m45.2m42.7m40.2m38.5m29.0m41.3m

Gross profit Margin, %

33%73%20%84%44%35%51%72%72%86%82%92%85%76%83%81%68%71%90%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

22.7m79.1m52.8m114.7m78.8m109.8m

Accounts Receivable

7.3m26.3m42.2m53.8m66.5m48.0m

Prepaid Expenses

1.7m15.1m10.3m15.1m

Inventories

1.3m15.0m11.4m5.1m8.3m6.6m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(18.0m)2.6m81.5m51.9m31.9m14.3m

Depreciation and Amortization

13.0k3.7m3.7m4.7m

Inventories

(1.3m)(13.8m)12.3m(2.4m)(5.6m)1.7m

Accounts Payable

2.9m356.0k10.7m(8.5m)(2.1m)(4.5m)
USDQ2, 2014

Financial Leverage

1.4 x
Show all financial metrics

Eagle Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Eagle Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Eagle Pharmaceuticals Online and Social Media Presence

Embed Graph

Eagle Pharmaceuticals News and Updates

Research Reveals Potential Growth Cancer Tubulin Inhibitors Market including key players Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals

HTF MI published a new industry research that focuses on Cancer Tubulin Inhibitors market and delivers in-depth market analysis and future prospects of Global Cancer Tubulin Inhibitors market. Posted via Industry Today. Follow us on Twitter @IndustryToday

Eagle Pharmaceuticals Frequently Asked Questions

  • When was Eagle Pharmaceuticals founded?

    Eagle Pharmaceuticals was founded in 2007.

  • Who are Eagle Pharmaceuticals key executives?

    Eagle Pharmaceuticals's key executives are Michael W. Cordera, Scott Tarriff and Daniel OConnor.

  • How many employees does Eagle Pharmaceuticals have?

    Eagle Pharmaceuticals has 108 employees.

  • What is Eagle Pharmaceuticals revenue?

    Latest Eagle Pharmaceuticals annual revenue is $195.9 m.

  • What is Eagle Pharmaceuticals revenue per employee?

    Latest Eagle Pharmaceuticals revenue per employee is $1.8 m.

  • Who are Eagle Pharmaceuticals competitors?

    Competitors of Eagle Pharmaceuticals include ASIT Biotech, Acousia Therapeutics and Vidac Pharma.

  • Where is Eagle Pharmaceuticals headquarters?

    Eagle Pharmaceuticals headquarters is located at 50 Tice Blvd #315, Woodcliff Lake.

  • Where are Eagle Pharmaceuticals offices?

    Eagle Pharmaceuticals has offices in Woodcliff Lake and Chicago.

  • How many offices does Eagle Pharmaceuticals have?

    Eagle Pharmaceuticals has 2 offices.